Last reviewed · How we verify
TDF/3TC/EFV
This is a fixed-dose combination antiretroviral regimen that inhibits HIV reverse transcriptase and integrase to suppress viral replication.
This is a fixed-dose combination antiretroviral regimen that inhibits HIV reverse transcriptase and integrase to suppress viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.
At a glance
| Generic name | TDF/3TC/EFV |
|---|---|
| Also known as | Tenofovir /Ravmidine /Efavirenz |
| Sponsor | Peking Union Medical College Hospital |
| Drug class | Antiretroviral combination therapy (NRTI + NNRTI) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
TDF (tenofovir disoproxil fumarate) and 3TC (lamivudine) are nucleoside reverse transcriptase inhibitors (NRTIs) that block HIV reverse transcriptase, while EFV (efavirenz) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that also targets the same enzyme through a different mechanism. Together, these three agents provide potent suppression of HIV-1 replication by preventing the conversion of viral RNA to DNA.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients
Common side effects
- Dizziness and CNS effects (EFV-related)
- Nausea
- Diarrhea
- Rash
- Headache
- Renal impairment (TDF-related)
- Bone density loss (TDF-related)
Key clinical trials
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine (PHASE3)
- Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028) (PHASE2)
- Good-first: B/F/TAF As First-line ART
- Impact of a Dolutegravir-based Regimen on Early Mortality of AIDS Patients (PHASE2, PHASE3)
- ANRS 12372 MODERATO Study (PHASE3)
- Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants (PHASE2)
- DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |